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Abstract: Molecularly imprinted polymers (MIPs) are tailor-made synthetic materials possessing 
memory of their molecular templates that have found numerous applications in separation science, 
drug delivery and catalysis. Here, we report the development of a MIP based on poly(2-oxazoline)s. 
The crosslinked imprinted polymer was obtained by reacting a short-chain poly(2-oxazoline) with 
methyl ester side chains with diethylenetriamine in the presence of indometacin as template. The 
crosslinker diethylenetriamine simultaneously acted as crosslinker and to interact with the 
indometacin template. The influence of several parameters on indometacin adsorption such as 
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initial concentration, contact time, and temperature as well as reusability of the MIPs and kinetics 
of indometacin release have been investigated. The maximum amount of indometacin bonded 
reached 293 mg g-1 for imprinted polymer vs. 25 mg g-1 for non-imprinted polymer. This result 
clearly indicates that molecularly imprinted poly(2-oxazoline)s possess a large potential for 
developing new MIPs due to their high imprinting properties. 
1. Introduction 
Molecularly imprinted polymers (MIPs) are polymers possessing antibody-like affinity towards 
particular molecules.1-3 The most common synthesis of MIPs involves copolymerization of a 
mixture of functional monomers and cross-linkers in the presence of template molecules. The 
functional monomers are responsible for forming intermolecular interactions with the template 
molecules, whereas the cross-linkers form the molecular scaffold around the template molecules 
during polymerization. An alternative method for the preparation of MIPs is by crosslinking of 
preformed polymers in the presence of the template in a so-called post-polymerization modification 
reaction.4-6 In this approach, the prepolymer can contain functional groups that interact with the 
template while additional interactive groups may be present in the crosslinker. Removal of the 
template molecules after synthesis allows to obtain MIPs that are selective towards the template 
molecules. The reason of the high selectivity is the fact that MIPs possess cavities that are 
complementary to the template molecules by size, shape and presence of particular functional 
groups. The advantage of MIPs over natural antibodies is their high thermal and chemical stability, 
excellent reusability and easy, low-cost synthesis.7 The MIPs have found numerous application in 
solid-phase extraction,8-10 catalysis,11-13 as sensors,14-16 and in drug delivery.17-20 
Drug delivery is the process or method that allows to transport drugs into the body to achieve the 
desired therapeutic effect.21 To maximize the efficiency and safety of medicines, drug delivery 
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systems should be able to regulate the release rate of a medicine to maintain its concentration in 
the therapeutic window and/or release it to a specific site.22,23 Based on their unique properties 
MIPs seem to be perfectly designed for controlled drug delivery, as the strength of their interactions 
with the template molecules can be tuned by changing the composition of functional monomers 
and cross-linkers, thereby enabling control over the drug release rate. Up to now, most MIPs are 
synthesized using methacrylates or vinyl monomers, which show limited hydrophilicity and low 
biocompatibility.24 These drawbacks are the reason to develop new types of MIPs which can be 
used as drug delivery systems.25 
Poly(2-oxazoline)s26-28 represent a group of polymers which are obtained by cationic ring-opening 
polymerization of 2-oxazolines.29 The properties of the final polymer may be altered by changing 
the side chain of 2-oxazoline monomer or by copolymerizing various monomers.30 In recent years, 
poly(2-oxazoline)s have received much attention due to their biocompatibility, stealth behavior and 
high synthetic versatility.31-33 As a result, they have found numerous biomedical applications such 
as drug delivery,34-36 preparation of micelles,37-39 drug conjugates,40-42 non-fouling coatings,43-45 
gene delivery,46-48 or preparation of hemostatic materials.49 
In this work, we report the synthesis of molecularly imprinted poly(2-oxazoline)s and their 
application in sustained release of the anti-inflammatory drug indometacin. To the best of our 
knowledge, this is the first study describing the synthesis of molecularly imprinted poly(2-
oxazoline)s. The limitations of cationic ring-opening polymerization of 2-oxazolines, particularly 
necessity to avoid presence of any nucleophilic groups, makes it challenging to imprint poly(2-
oxazoline)s during the polymerization. To overcome this limitation, we have prepared MIPs by 
crosslinking of short poly(2-oxazoline) prepolymers possessing methyl ester groups in their side 
chains using a direct amidation reaction with diethylenetriamine in the presence of indometacin as 
a template molecule. The crosslinker simultaneously acts as a functional monomer as it possesses 
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a free amine group which can interact with the template molecule. Within this paper, we present 
the physicochemical properties of the obtained MIPs as well as its ability for sustained release of 
indometacin. 
2. Experimental 
2.1. Materials and chemicals 
Methyl tosylate (MeOTs) was distilled and stored under argon. Indomethacin were obtained from 
TCI Europe. Glutaric anhydride, thionyl chloride, 2-chloroethylamine hydrochloride, 
diethylenetriamine, triethylamine, sodium chloride, thionyl chloride anhydrous sodium sulfate, and 
anhydrous sodium carbonate were obtained from Sigma-Aldrich and used as received. Methanol, 
chloroform, dimethylformamide, and dichloromethane (HPLC grade) were obtained from Sigma-
Aldrich. 
2.2. Instruments 
Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker DMC300 (300 MHz for 
1H, 75 MHz for 13C). UV–vis measurements were performed on a Varian Cary 100 Bio 
spectrophotometer using 1 cm quartz cuvettes. Polymerization was conducted in a Biotage Initiator 
Microwave System with Robot Sixty utilizing capped reaction vials. Scanning electron microscopy 
(SEM) images were obtained on a FEI Quanta 200F Microscope. All samples were placed on a 
carbon tape and covered with gold layer using sputter coating prior to analysis. The FTIR spectra 
were recorded on a Perkin Elmer Spectrum 1000 FTIR spectrometer in the 600 – 4000 cm-1 range 
using attenuated total reflectance (ATR) mode. Thermal data were obtained by using a Mettler 
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Toledo TGA/SDTA 851e. The thermal stability of the materials was investigated by 
thermogravimetric analysis in nitrogen stream at a heating rate of 10ºC min-1. 
2.3. Synthesis of 2-methoxycarbonylpropyl-2-oxazoline (C3MestOx) 
Four step synthesis of C3MestOx monomer was described in our previous work.50 Briefly, the 
sythesis involves reaction of glutaric anhydride with methanol to form monomethyl glutarate, 
which can be subsequetnly reacted with thionyl chloride to obtain glutaric acid monomethyl ester 
chloride. The obtained product is reacted with 2-chloroethylamine hydrochloride to form 
C3MestOx precursor. The last reaction is a ring closure reaction that occurs between C3MestOx 
precursor and anhydrous sodium carbonate. The final C3MestOx has to be distilled over barium 
oxide under vacuum before further use. 
2.4. Polymerization of C3MestOx 
C3MestOx monomer (24 mmol), MeOTs initiator (0.48 mmol) and acetonitrile (1.69 mL) were 
mixed under inert atmosphere in a microwave vial. The solution was polymerized in the microwave 
at 140ºC for 450 s. When finished, piperidine (0.2 mL) was added to terminate the polymer and the 
solution was stirred overnight at room temperature. The poly(C3MestOx) obtained (DP = 50) was 
precipitated by pouring the solution into cold diethyl ether. After removing all solvent the polymer 
was obtained as a sticky oil. 1H NMR (400 MHz, CDCl3): δ = 3.65 (br, -COO-CH3), 3.58-3.33 
(br, -N-CH2-CH2-N-), 2.49-2.22 (br, -CH2-CH2-CH2-), 1.98-1.75 (br, -CH2-CH2-CH2-). 
2.5. Poly(2-oxazoline) MIPs synthesis 
Poly(C3MestOx) (2.3363 g), diethylenetriamine (6.745 mmol) and indometacin (1.686 mmol) 
were dissolved in chloroform (10 mL) in a round bottom flask. The flask was placed in an oil bath 
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at 85ºC under a slight argon stream. After around 30 min. when most of the chloroform was 
evaporated, the mixture formed a rigid polymer. The reaction was continued overnight to allow full 
cross-linking. The polymer obtained (PAOx-MIP) was grinded, sieved using 40-mesh sieve and 
dialyzed against MeOH/NH3(aq) (95:5) three times and with MeOH two times to remove the 
template molecules. Afterwards, it was dried under vacuum at 40ºC to remove the solvent. 
A non-imprinted polymer (PAOx-NIP) was synthesized similarly to the MIPs but without the use 
of the indometacin template.  
2.6. Adsorption experiments 
The adsorption of indometacin on the PAOx-MIP and PAOx-NIP was examined using batch 
experiments. To prepare adsorption isotherms, a series of samples containing 10 mg of PAOx-MIP 
or PAOx-NIP were equilibrated for 48 h with 10 mL chloroform solution containing various 
concentrations of indometacin (0.01 mg mL-1 – 2 mg mL-1). The concentration of indometacin 
before and after adsorption was measured using UV-vis spectrophotometer. The amount of 
indometacin adsorbed (qeq; mg g
-1) was calculated using the following equation: 
𝑞𝑒𝑞 =
(𝐶0 − 𝐶𝑒𝑞)𝑉
𝑚
 (1) 
where C0 and Ceq are the initial and equilibrium concentrations (mg mL
-1), m is the mass of the 
polymer (g) and V is the solution volume (mL). All measurement were repeated in triplicate.  
For the adsorption kinetic studies 50 mg of PAOx-MIP or PAOx-NIP and 50 mL of indometacin 
chloroform solution at the initial concentration of 0.25 mg mL-1 were stirred at room temperature. 
The concentration of indometacin was measured at present time intervals using UV-vis 
spectrophotometer. The amount of indometacin adsorbed at time t (qt; mg g
-1) was calculated from: 
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𝑞𝑡 =
(𝐶0 − 𝐶𝑡)𝑉
𝑚
 (2) 
where Ct is the indometacin concentration at time t (h). 
Thermodynamic studies were performed for the sets of samples containing 20 mg of PAOx-MIP 
or PAOx-NIP and 10 mL of indometacin chloroform solution with the initial concentration of 0.25 
mg mL-1. The experiments were performed under 25, 33, 40, and 60ºC. Other experimental details 
were as for isotherms determination. 
Sorption/desorption experiments were performed in 48 h intervals for the sets of samples 
containing 20 mg of of PAOx-MIP or PAOx-NIP and 10 mL of indometacin chloroform solution 
with the initial concentration of 0.25 mg mL-1. After each adsorption the liquid phase was collected 
and the polymer was washed with MeOH/NH3(aq) (95:5) solution, followed by MeOH and dried. 
The concentration of indometacin before and after adsorption was measured using UV-vis 
spectrophotometer. To test the reusability of the polymers, this adsorption/desorption cycle was 
repeated five times with using the same adsorbent. 
2.7. In vitro drug release studies 
For the in vitro release studies 50 mg of PAOx-MIP containing indometacin were immersed in in 
phosphate buffered saline (PBS, pH 7.4) mixed with EtOH (70:30), and stirred at 37 °C. The second 
set of samples was immersed in HCl-KCl buffer (simulated gastro-intestinal conditions, pH 2.0) 
mixed with EtOH (70:30), and stirred at 37 °C. The concentration of indometacin was measured at 
present time intervals using UV-vis spectrophotometer. Total amounts of the drug released (FT; 
mg) were calculated as follows: 
𝐹𝑇 = 𝑉𝑚𝐶𝑡 (3) 
where Vm (mL) and Ct (mg mL
-1) are volume and indometacin concentration at time t. 
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The drug release data were fitted to different kinetic models. The data were analyzed using zero 
order (4), first order (5), Higuchi (6), and Hixon-Crowell (7) mathematical models. 
𝐹𝑡 = 𝑘𝑜𝑡 (4) 
𝐹𝑡 = 1 − 𝑒
−𝑘1𝑡 (5) 
𝐹𝑡 = 𝑘𝐻√𝑡 (6) 
√𝐹0
3 − √𝐹𝑡
3 = 𝑘𝐻𝐶𝑡 (7) 
where Ft is the fraction of the drug released at time t, F0 is the initial amount of the drug in the 
polymer, k0, k1, kH, and kHC are the release constants of the respective equations. 
3. Results and discussion 
3.1. Polymer synthesis and characterization 
The poly(2-oxazoline) based MIP was synthesized using poly(2-methoxycarbonylpropyl-2-
oxazoline) (poly(C3MestOx)) of DP = 50 as prepolymer, which is a short-chain poly(2-oxazoline) 
possessing methyl ester groups in the side chain. This polymer can be easily functionalized by a 
direct amidation reaction in order to produce more complex structures and introduce additional 
functionalities.51 The reaction with diethylenetriamine in the presence of the template indometacin 
resulted in a highly cross-linked molecularly imprinted poly(2-oxazoline) (Figure 1). The amount 
of diethylenetriamine used for the reaction was designed in such a way that two-thirds of the amine 
groups, presumably mostly the primary amine groups, could react with the poly(C3MestOx) methyl 
ester groups to form the highly crosslinked polymer scaffold, whereas the remaining amine groups 
are responsible for creating strong interactions with the template molecules. As a result, 
diethylenetriamine is simultaneously performing the role of a cross-linker and a functional 
interacting moiety. 
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Figure 1. Scheme of synthesis of PAOx-MIP with its proposed structure. 
 
The FT-IR absorbance spectra of as obtained, drug loaded, poly(2-oxazoline) MIP (PAOx-MIP), 
drug unloaded PAOx-MIP and the corresponding poly(2-oxazoline) non-imprinted polymer 
(PAOx-NIP), that was prepared under the same conditions in absence of the template, are presented 
in Figure 2. All three polymers display similar characteristic peaks in the IR spectra, indicating that 
the main structure of both polymers is identical. All spectra show absorption bands at 3282 cm-1 (ν 
N-H, broad band), 2930 cm-1 (ν C-H), 1730 cm-1 (ν C=O) of residual ester groups, 1636 cm-1 (ν 
C=O, strong band), and 1548 cm-1 (δ N-H). The loaded PAOx-MIP shows additional signals at 
1213 cm-1 and 746 cm-1 confirming the presence of indometacin. Moreover, some differences in 
the FT-IR absorbance spectra can be observed. First of all, the comparison of IR spectra of loaded 
PAOx-MIP and PAOx-NIP or unloaded PAOx-MIP in the region around 3500 cm-1 (the region 
where N-H stretching vibration is observed) showed differences in the signal’s structure which lead 
to assumption that some interaction between the polymer amide groups and indomethacin are 
formed, presumably hydrogen bonding. Secondly, a new signal at 1093 cm-1 appeared in the loaded 
PAOx-MIP IR spectrum, which is not present in the PAOx-NIP, the unloaded PAOx-MIP nor the 
pure indomethacin spectra. This signal is probably the result of interactions formed between the 
polymer amide groups and the methoxy group of indomethacin. We propose that this signal is a C-
O stretching vibration shifted due to formation of interactions with the polymer amide groups. 
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Figure 2. FT-IR spectrum of drug unloaded PAOx-MIP, drug loaded PAOx-MIP and PAOx-NIP. 
 
The exemplary SEM images of loaded PAOx-MIP, unloaded PAOx-MIP and PAOx-NIP are 
presented in Figure 3. All polymers have a uniform, smooth surface, which is probably a result of 
the high degree of cross-linking. There are no visible differences in the morphology of loaded 
PAOx-MIP, unloaded PAOx-MIP and PAOx-NIP. 
 
 
 
Figure 3. SEM image of (a) drug loaded PAOx-MIP, (b) drug unloaded PAOx-MIP and (c) PAOx-
NIP. 
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The results of thermogravimetric analysis (TGA) of loaded PAOx-MIP, unloaded PAOx-MIP and 
PAOx-NIP are presented in Figure 4. For all polymers very similar results were obtained and two 
main steps can be observed. The first one starts at around 80ºC and ends around 300ºC and is 
connected with continuous removal of solvents and water that is enclosed in the crosslinked 
polymers. The second step in TGA starts at around 300ºC and ends at around 430ºC and is 
connected with the decomposition of the polymer. The mass loss (%) during this step is slightly 
lower for the loaded PAOx-MIP compared to the two other polymers, which clearly indicated that 
some additional non-volatile material is present in the residue. This observation is in accordance 
with the fact that the polymer contains indometacin in its structure, which is not fully decomposed 
into volatile material under nitrogen atmosphere. 
 
 
Figure 4. TG results of drug loaded PAOx-MIP, drug unloaded PAOx-MIP and PAOx-NIP. 
3.2. Adsorption isotherms 
Adsorption isotherms are used to characterize the adsorption process of MIPs at the equilibrium 
state. Figure 5 shows the relationship between the equilibrium concentration of indometacin and 
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the amount that is adsorbed by PAOx-MIP or PAOx-NIP. To describe the adsorption process 
Langmuir and Freundlich adsorption isotherm models were used to fit the experimental data. 
 
Figure 5. Adsorption isotherms of indometacin onto PAOx-MIP and PAOx-NIP. 
 
 
The Langmuir adsorption isotherm is mathematically expressed as  
𝐶𝑒𝑞
𝑞𝑒𝑞
=
𝐶𝑒𝑞
𝑞𝑚
+
1
𝐾𝑞𝑚
 (8) 
where K (L mg-1) is the binding equilibrium constant, qm (mg g
-1) is the maximum amount of 
indometacin bonded, Ceq (mg L
-1) is the equilibrium concentration of indometacin, and eeq (mg g
-
1) is the amount of indometacin bonded at the concentration Ceq. The calculated K, qm and 
correlation coefficients (R2) values are presented in Table 1. The R2 values obtained for PAOx-
MIP and PAOx-NIP are 0.974 and 0.956, respectively, which indicates that the experimental data 
obtained for the PAOx-MIP and PAOx-NIP can be well-described by the Langmuir adsorption 
model. The qm value calculated for the PAOx-MIP is over one order of magnitude higher than the 
one calculated for PAOx-NIP. This result clearly indicates that the imprinting was successful and 
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that molecularly imprinted poly(2-oxazoline)s provide a large potential for developing new MIPs 
due to their high imprinting properties. 
 
Table 1. Parameters of analyte indometacin adsorption by PAOx-MIP and PAOx-NIP 
Polymer 
Langmuir Freundlich 
qm (mg g-1) K (L mg-1) R2 Kf (mg g-1 (L mg-1)1/n) 1/n R2 
PAOx-MIP 293 ± 10 0.003 ± 0.001 0.974 2.14 ± 0.08 0.72 ± 0.06 0.980 
PAOx-NIP 25 ± 2 0.004 ± 0.001 0.956 0.50 ± 0.06 0.54 ± 0.05 0.983 
 
The Freundlich adsorption isotherm is mathematically expressed as 
𝑞𝑒𝑞 = 𝐾𝑓𝐶𝑒𝑞
1 𝑛⁄
 (9) 
log 𝑞𝑒𝑞 = log𝐾𝑓 +
1
𝑛
log 𝐶𝑒𝑞 (10) 
where Kf and n represent the Freundlich constants, Ceq (mg L
-1) is the equilibrium concentration of 
indometacin, and qeq (mg g
-1) is the amount of indometacin adsorbed at the concentration Ceq. The 
calculated Kf, 1/n, and correlation coefficient (R
2) values are given in Table 1. The R2 values 
obtained for PAOx-MIP and PAOx-NIP are 0.980 and 0.983, respectively, which indicates that 
especially for the PAOx-NIP the Freundlich isotherm agrees better with experimental data than the 
Langmuir adsorption model. For the PAOx-MIP the R2 value is almost identical as the one obtained 
for Langmuir model, which indicates that both models describe the adsorption by PAOx-MIP well. 
The value of 1/n ranging between 0 and 1 is a measure of adsorption intensity or surface 
heterogeneity. The surface is more heterogeneous when the value of 1/n gets closer to zero.52 The 
values of 1/n are 0.72 and 0.50 for PAOx-MIP and PAOx-NIP, respectively which indicates that 
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the PAOx-NIP has a more heterogeneous surface than PAOx-MIP, which explains why the PAOx-
NIP has a worse fit with the Langmuir isotherm model. 
3.3. Adsorption kinetics 
The influence of the interaction time on the adsorption capacity was studied to evaluate the 
adsorption kinetics. Two kinetic models were applied to characterize the adsorption process. The 
first model is the pseudo-first-order model given by Langergren and Svenska which is expressed 
as: 
log(𝑞𝑒 − 𝑞𝑡) = log 𝑞𝑒 −
𝑘1
2.303
𝑡 (11) 
where qe and qt are the amount of substrate adsorbed (mg g
-1) at equilibrium and at time t (h), 
respectively, and k1 (h
-1) is the pseudo-first-order rate constant. The plots of log(qe – qt) versus t is 
presented in Figure 6 and the k1 and R
2 values are given in Table 2. The R2 values are relatively 
high which indicates that the pseudo-first-order model can be applied to describe the kinetics of 
the adsorption of indometacin onto PAOx-MIP and PAOx-NIP. 
 
Figure 6. Pseudo-first-order kinetic model for indometacin adsorption onto PAOx-MIP and PAOx-
NIP. 
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Table 2. Kinetic parameters calculated for pseudo-first-order and pseudo-second-order models 
Polymer 
Pseudo-first-order 
kinetic 
Pseudo-second-order 
kinetic 
k1 (h-1) R2 k2 (g mg-1 h-1) R2 
PAOx-
MIP 
0.026±0.005 0.989 0.0003±0.0001 0.677 
PAOx-
NIP 
0.058±0.006 0.967 0.0074±0.0008 0.936 
 
The second model applied is the pseudo-second-order model based on the equilibrium adsorption 
which can be mathematically expressed as: 
𝑡
𝑞𝑡
=
1
𝑘2𝑞𝑒2
+
1
𝑞𝑒
𝑡 (12) 
where k2 (g mg
-1 h-1) is the pseudo-second-order rate constant. The plots of t/qt versus t is presented 
in Figure 7 and the k2 and R
2 values are given in Table 2. The R2 value calculated for adsorption 
of indometacin on PAOx-MIP is very low (0.677) indicating that this model cannot be applied to 
characterize this adsorption process. The R2 value calculated for adsorption of indometacin on 
PAOx-NIP is also lower than the one calculated for the pseudo-first-order model. However, for the 
PAOx-NIP the differences in R2 values between the two theoretical models are not as high as for 
PAOx-MIP. This result suggests, that the mechanism of adsorption of indometacin on PAOx-MIP 
and PAOx-NIP is different. 
16 
 
 
Figure 7. Pseudo-second-order kinetic model for indometacin adsorption onto PAOx-MIP and 
PAOx-NIP. 
3.4. Adsorption thermodynamics 
Performing adsorption experiments at various temperatures allows to evaluate the thermodynamic 
parameters such as enthalpy (ΔH), entropy (ΔS) and Gibbs free energy (ΔG) for adsoption. The 
values of ΔH and ΔS were calculated using the equation: 
ln 𝐾𝑑 =
∆𝑆
𝑅
−
∆𝐻
𝑅𝑇
 (13) 
where R (8.314 J mol-1 K-1) is the universal gas constant, T (K) is the temperature at which 
adsorption occurs and Kd is the distribution coefficient which is defined as: 
𝐾𝑑 =
𝐶𝐴𝑒
𝐶𝑒
 (14) 
where CAe is the amount adsorbed on solid (mmol g
-1) and Ce is the equilibrium concentration 
(mmol mL-1). The ΔG value was calculated using the equation: 
∆𝐺 = −𝑅𝑇 ln𝐾𝑑 (15) 
The calculated values of ΔH, ΔS and ΔG are presented in Table 3. For the PAOx-MIP the 
determined ΔH value is negative which means that the adsorption is an exothermic process. On the 
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other hand, for the PAOx-NIP the ΔH value was found to be positive indicating that the 
indometacin adsorption on this polymer is an endothermic process, most likely driven by the 
release of solvating solvent molecules upon adsorption. These results clearly indicates that the 
mechanism of adsorption for both polymers is different, which is in accordance with other results 
presented in this study. For both polymers, the ΔS values are positive indicating an increase in 
randomness during the adsorption process due to release of solvent molecules. For the PAOx-NIP 
this increase is much higher, as the adsorption of indometacin by this polymer is driven by entropy. 
The overall negative values of ΔG indicate that adsorption is spontaneous. 
 
Table 3 Thermodynamic parameters obtained for process of indometacin adsorption 
Polymer ∆H (kJ mol-1) 
∆S (J mol-1 
K-1) 
∆G (kJ mol-1) 
25 (ºC) 33 (ºC) 40 (ºC) 60 (ºC) 
POxMIP -8.30± 0.35 26.99± 0.52 -16.19±0.23 -16.61±0.19 -16.95± 0.26 -17.16± 0.31 
POxNIP 16.86± 0.48 90.77± 0.84 -9.89± 0.21 -11.07±0.17 -11.86±0.24 -13.16± 0.29 
 
3.5. Adsorption/desorption cycles 
The reusability of PAOx-MIP was examined in five cycles of adsorption/desorption and the results 
are summarized in Figure 8. The adsorption capacity of PAOx-MIP after five cycles is still above 
90% of the initial adsorption capacity. This result clearly shows that molecularly imprinted poly(2-
oxazoline)s can be successfully reused after release of the previously adsorbed molecules. 
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Figure 8. Reusability efficiency of PAOx-MIP for the adsorption of indometacin. 
3.6. In vitro release studies 
The in vitro release studies of indometacin from PAOx-MIP (50 mg) were carried in 50 mL of PBS 
(pH 7.4)/EtOH (70:30) solution and 50 mL of HCl-KCl (pH 2.0)/EtOH (70:30) solution to study 
the release behavior in simulated intravenous conditions and gastric fluid, respectively. The release 
medium was incubated in 37 °C with constant stirring at 120 rpm. At fixed time intervals samples 
were withdrawn (200 µL) and replenished with the same volume of fresh release medium. 
Introduction of ethanol into the buffer solutions was required to counteract the very low solubility 
of indometacin in water, which is a common procedure for studying the drug release of poorly 
soluble drugs.53 The indometacin release profiles (Figure 9) demonstrate different behavior 
depending on the pH of the release medium. At pH 7.4 the release of indometacin is a steady 
process which reaches over 90% release in 4 hours. When the drug-loaded PAOx-MIP was 
immersed in pH 2.0 buffer, a slower release was observed, but ultimately, a 90% release was also 
reached within 5 hours. The slower release at lower pH may be ascribed to complete protonation 
of the secondary amine groups, thereby altering the interaction with indometacin, and/or the lower 
solubility of indomethacin at pH 2 where its carboxylic acid will be protonated. 
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Figure 9. In-vitro release of indometacin from drug-loaded PAOx-MIP at pH = 7.4 and pH = 2.0. 
 
The experimental data obtained from indometacin release was analyzed using several mathematical 
models, which are applied for characterization of drug release from polymeric materials. The 
release profiles obtained for pH 7.4 and pH 2.0 were fitted to zero order, first order, Higuchi, and 
Hixson-Crowell theoretical models. The values of corresponding release constants k and 
correlation coefficients (R2) are collected in Table 4. The release of indometacin from the PAOx-
MIP at pH 7.4 can be partially fitted with Higuchi model (R2 = 0.909), whereas for other release 
models the R2 values are very low. The Higuchi model is based on Fick’s law, therefore it can be 
assumed that the release mechanism is mostly based on Fickian diffusion.54 The release of 
indometacin from the PAOx-MIP at pH 2.0 is nicely fitted with the Higuchi model (R2 = 0.987). 
For first order and Hixson-Crowell models, the obtained R2 values are low (0.658 and 0.786, 
respectively), whereas for the zero order model a moderate R2 value of 0.919 was obtained. This 
result indicates that the release mechanism is based on Fickian diffusion. Noticeable differences in 
R2 values for indometacin release at pH 7.4 and 2.0 obtained for the Higuchi model indicates that 
although both mechanisms are based on Fickian diffusion they are not identical. 
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The fact that both release mechanisms are based on Fickian diffusion but they are not identical is 
probably caused by difference in processes that lead to drug release. At pH 7.4 the solubility of 
indometacin is higher than at pH 2.0, therefore under these conditions the release of the drug is 
determined by the kinetics of desorption and diffusion from polymer structure into the solution.55 
At pH 2.0 the solubility of indomethacin is lower, therefore the initial release is slower than at pH 
7.4. However, the protonation of the amine groups which are responsible for the interactions with 
drug molecules takes place, which is also dependent on the diffusion of hydronium ions into the 
polymer structure. As a result, after full protonation the ultimate amount of drug released is higher 
than for pH 7.4. 
Table 4. Release kinetic data of indometacin from drug-loaded PAOx-MIP 
Buffer 
pH 
Zero order First order Higuchi Hixson-Crowell 
k0 (h-1) R2 k1 (h-1) R2 kH (h-1/2) R2 kHC (h-1/3) R2 
7.4 9.58 ± 0.43 0.661 0.20 ± 0.08 0.421 35.1 ± 1.2 0.909 -0.23 ± 0.06 0.516 
2.0 14.2 ± 0.67 0.919 0.37 ± 0.11 0.658 41.1 ± 1.9 0.987 -0.40 ± 0.08 0.786 
 
4. Conclusions 
In conclusion, we have shown that molecularly imprinted poly(2-oxazoline)s can be easily 
synthesized using short side-chain functional poly(2-oxazoline)s and appropriate cross-linking 
reagents. This new type of MIP was characterized using various analytical techniques and showed 
satisfactory thermal and chemical stability. Its adsorption properties towards the template 
indometacin molecules were investigated. The adsorption process was nicely characterized by 
Langmuir and Freundlich adsorption models, whereas the adsorption process for the non-imprinted 
polymer followed the Freundlich adsorption model. The maximum calculated amount of 
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indometacin bonded for the imprinted polymer was over one order of magnitude higher than the 
one calculated for non-imprinted. Significant differences for the imprinted and non-imprinted 
polymer were observed for the adsorption thermodynamics. For the imprinted polymer, adsorption 
is an exothermic process, whereas for the non-imprinted polymer, adsorption is an endothermic 
process. These results clearly indicate that the mechanism of adsorption for both polymers is 
different. Kinetics of adsorption for both polymers was nicely described by the pseudo-first-order 
kinetic model. The release kinetics of indometacin from drug-loaded imprinted polymer showed 
that Higuchi model was appropriate to describe the release process at pH 7.4 and 2.0.  
In summary, the obtained poly(2-oxazoline) based MIP possesses a large potential for developing 
a new group of MIPs due to its very high imprinting capacity. The results obtained indicate that 
molecularly imprinted poly(2-oxazoline)s are a promising materials to be used for biomedical 
applications. 
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